Rapidly Enlarging Diffuse Large B-Cell Lymphoma Presenting 20 Years after Hodgkin’s Lymphoma: A Case Report

Madison Drallmeier^1, , Katherine King¹ and Richard C. Spinale²

¹Michigan State University College of Osteopathic Medicine, East Lansing, MI, USA

²Department of General Surgery, Garden City Hospital, Garden City MI, USA

Cite this paper

Madison Drallmeier, Katherine King and Richard C. Spinale. Rapidly Enlarging Diffuse Large B-Cell Lymphoma Presenting 20 Years after Hodgkin’s Lymphoma: A Case Report. American Journal of Medical Case Reports. 2022; 10(10):253-255. doi: 10.12691/AJMCR-10-10-1

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma diagnosed in the United States. DLBCL often presents with constitutional symptoms, lymphadenopathy, and mass. Here we report a case of asymptomatic DLBCL with a rapidly enlarging mass as the presenting symptom. Given the patient’s history of Hodgkin lymphoma, his DLBCL is likely a secondary malignancy resulting from previous chemotherapy and radiation.

Keywords

Hodgkin lymphoma, diffuse large B-cell lymphoma, secondary malignancy

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	SEER Cancer Stat Facts: Diffuse Large B-Cell Lymphoma. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/dlbcl.html.
[2]	Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., Jaffe E.S., “The 2016 revision of the World Health Organization classification of lymphoid neoplasms,” Blood, 127 (20). 2375-90. May 2016.
[3]	Scott D.W., Mottok A., Ennishi D., Wright G.W., Farinha P., Ben-Neriah S., Kridel R., Barry G.S., Hother C., Abrisqueta P., Boyle M., Meissner B., Telenius A., Savage K.J., Sehn L.H., Slack G.W., Steidl C., Staudt L.M., Connors J.M., Rimsza L.M., Gascoyne R.D., “Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies,” J Clin Oncol, 33 (26), 2848-56. Sep 2015
[4]	Li S., Young K.H., Medeiros L.J., “Diffuse large B-cell lymphoma,” Pathology., 50 (1), 74-87. Jan 2018.
[5]	Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Müller-Hermelink H.K., Campo E., Braziel R.M., Jaffe E.S., Pan Z., Farinha P., Smith L.M., Falini B., Banham A.H., Rosenwald A., Staudt L.M., Connors J.M., Armitage J.O., Chan W.C., “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray,” Blood, 103 (1), 275-82. Jan 2004.
[6]	Nguyen L., Papenhausen P., Shao H., “The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects.,” Genes (Basel), 8 (4), 116. Apr 2017.
[7]	Mondello P., Mian M., “Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP,” Hematol Oncol, 37 (4), 333-344. Oct 2019.
[8]	Wilson W.H., Dunleavy K., Pittaluga S., Hegde U., Grant N., Steinberg S.M., Raffeld M., Gutierrez M., Chabner B.A., Staudt L., Jaffe E.S., Janik J.E., “Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers,” J Clin Oncol, 26 (16), 2717-24. Jun 2008.
[9]	Bartlett N.L., Wilson W.H., Jung S.H., Hsi E.D., Maurer M.J., Pederson L.D., Polley M.C., Pitcher B.N., Cheson B.D., Kahl B.S., Friedberg J.W., Staudt L.M., Wagner-Johnston N.D., Blum K.A., Abramson J.S., Reddy N.M., Winter J.N., Chang J.E., Gopal A.K., Chadburn A., Mathew S., Fisher R.I., Richards K.L., Schöder H., Zelenetz A.D., Leonard J.P., “Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 5030,”. J Clin Oncol, 37 (21), 1790-1799. Jul 2019.
[10]	Negrean V., Graur F., Moiş E., Al-Hajjar N., “Ileocecal Obstruction Due to B-cell Non-Hodgkin Lymphoma,” Chirurgia, 111 (1),71-3. 1990.
[11]	Ravindhran B., Prakash C., Govindharaj S., Bahnou N.M.S., Pavithra B., “An Aggressive Primary Retroperitoneal Diffuse Large B-Cell Lymphoma Mimicking a Pancreatic Neoplasm, Presenting as Duodenal Stenosis,” J Clin Diagn Res, 11 (9), 9-11. Sep 2017.
[12]	Krikorian J.G., Burke J.S., Rosenberg S.A., Kaplan H.S., “Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease,” N Engl J Med, 300 (9), 452-8. Mar 1979.
[13]	Swerdlow A.J., Higgins C.D., Smith P., Cunningham D., Hancock B.W., Horwich A., Hoskin P.J., Lister T.A., Radford J.A., Rohatiner A.Z., Linch D.C., “Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study,” J Clin Oncol, 29 (31), 4096-104. Nov 2011.
[14]	Schaapveld M., Aleman B.M., van Eggermond A.M., Janus C.P., Krol A.D., van der Maazen R.W., Roesink J., Raemaekers J.M., de Boer J.P., Zijlstra J.M., van Imhoff G.W., Petersen E.J., Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg P.J., van Leeuwen F.E., “Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma,” N Engl J Med, 373 (26), 2499-511. Dec 2015.